Welcome to the latest MHRA GDP blog post! I’m Claire Glenister, a GDP Inspector who has been working for the agency for 3 years. This blog is to communicate highlights from the 2015 GDP days at the MHRA Symposium, at …
My name is Balall Naeem and I have been with the MHRA for more than 10 years now. In that time, I have worked across 3 different Divisions in a number of roles. The ones most relevant for this topic would …
We are aware there is some concern for UK business and personal careers, over the status of transitional QPs that were recognised under the transitional arrangements provided in SI 2004/1031, when the Clinical Trials Directive was implemented in 2004. The …
Late last year the GPvP inspectorate ran its own symposium and contributed heavily to the EU pharmacovigilance inspector training event. GPvP symposium The GPvP inspectorate held a sell-out symposium in London in November attended by approximately 350 delegates. GPvP inspectors highlighted requirements, …
Patient safety is the end objective for manufacturers, wholesalers, distributors and those healthcare professionals administering to patients. This blog is in 2 parts and draws on some of the findings from good distribution practice (GDP) inspections, references to the EU GDP …
Happy New Year! Having pestered my team for ideas for the blog and articles it seems only fair I start 2016 by writing one myself, with a focus on stakeholder engagement and the new EU Clinical Trials Regulation update. My …
